Seroconversion in Membranous Nephropathy: From Seronegative to Seropositive Disease (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0688; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "He was re-initiated on mycophenolate mofetil and rituximab prior to relocating and lost to follow-up. Alternatively, the circulating PLA2R levels could be below the detection threshold of the assay, consistent with the early-stage MN lesions found histologically and suggesting low-level disease activity. Our experience highlights the role of longitudinal monitoring of PLA2R antibodies, even in cases with an initial negative result, for accurate classification and management of renal allograft recipients."
Glomerulonephritis • Nephrology • Renal Disease • Transplant Rejection
|
|
Kiersten M. Preuss; Kevin Paul Trappett; Geoffrey Talmon; Kirk W. Foster; Brian Joseph Benes
|